Search results
Showing 136 to 150 of 181 results for transplantation
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults.
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)
Evidence-based recommendations on ponatinib (Iclusig) for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia in adults.
Evidence-based recommendations on photochemical corneal cross linkage using riboflavin and ultraviolet A for keratoconus. This involves using special eye drops and exposing the eye ultraviolet light, with the aim to strengthen the cornea.
Evidence-based recommendations on lenalidomide (Revlimid) for treating multiple myeloma in adults who have had at least 2 prior therapies.
Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (HTE2)
Evidence-based recommendations on cefiderocol for treating severe drug-resistant gram-negative bacterial infections....
Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections....
View recommendations for HTE1Show all sections
Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making
This guidance has been updated and replaced by NICE interventional procedure guidance 535.
This guideline covers assessing and managing chronic hepatitis B in children, young people and adults. It aims to improve care for people with hepatitis B by specifying which tests and treatments to use for people of different ages and with different disease severities.
Discontinued [GID-IP1046]
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (TA193)
Evidence-based recommendations on rituximab for treating relapsed or refractory chronic lymphocytic leukaemia in adults.
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma in adults after 2 or more systemic therapies.
Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making
Immunosuppressive therapy for renal transplantation in adults (TA85)
This guidance has been updated and replaced by NICE technology appraisal guidance 481.
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. See our guideline on renal replacement therapy and conservative management and for people with COVID-19 see our guideline on managing COVID-19.